Allergic Rhinitis, Asthma and COPD Therapeutics Practice Test

In the management of Group B Chronic Obstructive Pulmonary Disease (COPD), the preferred treatment is a combination of a Long-Acting Beta-Agonist (LABA) and a Long-Acting Muscarinic Antagonist (LAMA). This combination therapy is recommended because it offers a synergistic effect on bronchodilation, which improves lung function and reduces symptoms more effectively than using either class of medication alone.

Group B COPD is characterized by patients who have a more significant symptom burden but fewer exacerbations. The goal of treatment at this stage is to improve the quality of life and reduce respiratory symptoms, making the LABA + LAMA combination optimal. Each medication targets different pathways in the airways, allowing for better overall control of COPD symptoms.

Additionally, using this combination has been shown in clinical trials to significantly reduce exacerbation rates and improve lung function. In contrast, other options like short-acting bronchodilators or monotherapy with either LAMA or LABA are generally reserved for less severe COPD or as rescue medications, rather than for consistent long-term management in patients with the symptomatology characteristic of Group B COPD.